Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 11/20 | 0.80 |
| ▸ | AURKA | O14965 | 7/20 | 0.71 |
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | BTK | Q06187 | 1/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.55 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL654905 | 0.89 | SYK (1.00) | SYKAURKAEGFRBTKMAPK8 | |
| SCHEMBL655352 | 0.87 | AURKA (0.77) | SYKAURKAEGFRBTKMAPK8 | |
| SCHEMBL1038552 | 0.85 | GLO1 (0.72) | SYKAURKAEGFRBTK | |
| SCHEMBL13185235 | 0.84 | SYK (0.85) | SYKAURKAEGFRBTK | |
| SCHEMBL655134 | 0.80 | SYK (0.77) | SYKAURKA | |
| SCHEMBL657059 | 0.80 | SYK (0.77) | SYKAURKA | |
| SCHEMBL15007350 | 0.78 | SYK (0.67) | SYKAURKAEGFRMAPK8AURKB | |
| SCHEMBL30878826 | 0.78 | CYP1A2 (0.62) | SYKEGFRMAPK8 | |
| SCHEMBL14771968 | 0.78 | SYK (0.74) | SYKAURKAEGFRBTK | |
| SCHEMBL21443446 | 0.78 | SYK (0.74) | SYKAURKAEGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | SYK 180/4885AURKA 895/4885EGFR 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.